Result of AGM

Physiomics plc (AIM: PYC), an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that all resolutions put to shareholders at the Company’s annual general meeting, held earlier today at the Company’s offices in Oxford, were duly passed.





Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980


Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341


Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494


Notes to Editor


About Physiomics


Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys.


Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.


Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.